Project description DEENESFRITPL AI for lung fluid congestion monitoring Heart failure (HF) is one of the most frequent causes of hospitalisation and premature death around the world. Patients who survive HF and return home need to remain under continuous monitoring so that any complications from lung fluid congestion are immediately treated. Unfortunately, these are often diagnosed very late. The EU-funded ReDS project is developing a medical device enabling easy, quick monitoring of lung congestion from the patient's home. It's non-invasive, connected with an artificial intelligence-based platform that manages collected data and sends it automatically to the care-centre. A special algorithm helps the doctor to prescribe proper treatment according to a patient's situation. Show the project objective Hide the project objective Objective Heart failure (HF) is one of the main causes of mortality and hospitalization worldwide, affecting around 26M people globally, and the most common cause of hospitalization for people over 65. Lung fluid congestion is one of the main HF-related clinical conditions, which leads to a vicious cycle of repeated hospitalizations of HF patients. Strikingly, 1 in 4 patients are readmitted to the hospital within 30 days, and 1 in 2 patients within 6 months. The key challenge is to enable early detection, continuous monitoring and timely treatment of symptoms before the patient undergoes respiratory distress. In fact, current lung fluid monitoring practices are mostly inaccurate and inefficient, enabling detection only at very advanced stages, when symptoms cannot be prevented by simply changing the medication. Sensible introduces ReDS™, a non-invasive home monitoring system for lung fluid congestion in HF patients. The monitoring procedure can be performed by the patient at home in just 90 seconds. The results are processed by an Artificial Intelligence (AI)-driven patient management platform and sent automatically to the physician. The unique proprietary AI algorithm supports physicians in identifying the best treatment based on each patients’ needs and general health status. ReDS™ is the first solution that enables accurate, remote monitoring and management of fluid congestion in HF patients after discharge.During the phase 1 feasibility study, Sensible will define a minimum viable product, establish a sound go-to-market strategy and supply chain, and draft further development plans. During the second phase of the innovation project, Sensible will optimize the device engineering for home use, optimize the AI algorithm, scale-up device manufacturing and perform clinical validation with partner hospitals. Fields of science natural sciencescomputer and information sciencesartificial intelligencesocial sciencessociologydemographymortalitymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsengineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologyradarmedical and health sciencesclinical medicinecardiology Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SENSIBLE MEDICAL INNOVATIONS LTD Net EU contribution € 50 000,00 Address Meir ariel 6 4059300 Netanya Israel See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
